Topline Bio x Uromigos
In this clip, the Uromigos discuss the combination of Abiraterone/Cabazitaxel and its modest clinical benefit in taxane-refractory mCRPC...so, the big question... is it likely to affect clinical practice?
The emergence of more active bladder cancer systemic therapy has led to more patients with initial advanced disease who could be considered for consolidative cystectomy. The Uromigos debate the timing and role of this maneuver.
The Uromigos focus on CDK 4/6 inhibition. CDK 4/6 did not produce benefit in mCRPC in a large phase 3 trial and the role of CDK inhibition in prostate cancer remains uncertain.
Chemotherapy plus nivolumab has benefit in advanced bladder cancer, especially in the biologically-distinct subset of patients with lymph node only disease.
In this episode, the Uromigos discuss Enfortumab vedotin (EV), an active agent in advanced bladder cancer and its efficacy/toxicity related to drug exposure. Early recognition and management of toxicity is critical.
Chromophobe RCC is a rare subtype of kidney cancer. Clinical outcomes from a large institution-based cohort are presented supporting IO-based combination therapy.
KIM-1 is a soluble protein with prognostic and predictive potential in resected RCC. Data from IMmotion 010 is discussed